Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemoglobin-based red blood cell substitutes.

Thomas Ming Swi Chang1

  • 1Artificial Cells and Organs Research Centre, MSSS-FRSQ Research Group on Blood Substitutes in Transfusion Medicine, McGill University, Montreal, Quebec, Canada.

Artificial Organs
|August 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Cells: Perspective on Reconstructing Biological Cells and "Out of the Box" Innovations.

Chembiochem : a European journal of chemical biology·2026
Same author

Intracellular Targeted Nanocapsules Containing Nanobiotherapeutic Suppress Lung, Liver, Breast and Cervix Cancer Cell Lines by Prodrug Activation or Removal of Intracellular Tyrosine.

Cancers·2025
Same author

Biodegradable Polylactide Nanocapsules Containing Quercetin for In Vitro Suppression of Mouse B16F10 and Human Sk-Mel-28 Melanoma Cell Lines.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Superparamagnetic polyhemoglobin-tyrosinase nanocapsules: a novel biotherapeutic with enhanced tumor suppression with control by external magnetic field.

Frontiers in bioengineering and biotechnology·2025
Same author

Superparamagnetic Artificial Cells PLGA-Fe<sub>3</sub>O<sub>4</sub> Micro/Nanocapsules for Cancer Targeted Delivery.

Cancers·2023
Same author

Editorial: Innovative medical technology based on artificial cells, including its different configurations.

Frontiers in medical technology·2023
Same journal

Large-Eddy Simulation of the FDA Benchmark Blood Pump: Validation Against Experiments and Implications for Turbulent Flow Mechanisms.

Artificial organs·2026
Same journal

The Warm Revolution: A Meta-Analysis of DCD Versus DBD Liver Transplant Outcomes in the Normothermic Machine Perfusion Era.

Artificial organs·2026
Same journal

Toward Optimal Remote Monitoring in LVAD Recipients: Remaining Challenges Beyond Feasibility.

Artificial organs·2026
Same journal

Advancing Organ Preservation and Perfusion: Introducing the International Society of Organ Preservation and Perfusion Therapy (ISOPPT).

Artificial organs·2026
Same journal

Short Inter-Treatment Interval Treatment With Artificial Liver Support System Reduces 90-Day Transplant-Free Mortality in Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure: A Retrospective Observational Study.

Artificial organs·2026
Same journal

Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.

Artificial organs·2026
See all related articles

Artificial oxygen carriers like polyhemoglobin are advancing in human clinical trials, with some already approved. Innovations include modified hemoglobin and nanotechnology for enhanced artificial red blood cells.

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Materials Science

Background:

  • Hemoglobin-based oxygen carriers (HBOCs) are being developed as blood substitutes.
  • Existing HBOCs face challenges like nitric oxide scavenging and potential toxicity.
  • Advancements are needed to improve efficacy and safety for clinical applications.

Purpose of the Study:

  • To review the current state and future directions of artificial red blood cell development.
  • To highlight innovations in hemoglobin modification and delivery systems.
  • To address challenges in clinical translation and therapeutic potential.

Main Methods:

  • Clinical trials of polyhemoglobin and conjugated hemoglobin.
  • Modification of recombinant hemoglobin to modulate nitric oxide effects.

Related Experiment Videos

  • Development of systems with antioxidant enzymes.
  • Encapsulation of hemoglobin in lipid vesicles and nanostructures.

    • Main Results:

    • Polyhemoglobin is in late-stage human clinical trials, with one product approved in South Africa.
    • Conjugated hemoglobin is undergoing clinical trials.
    • Recombinant hemoglobin modifications aim to improve oxygen delivery and reduce side effects.
    • Nanotechnology enables the creation of artificial red blood cells with enhanced properties.

    Conclusions:

    • Artificial red blood cells are progressing towards clinical viability.
    • Ongoing research focuses on overcoming limitations and expanding therapeutic applications.
    • Novel formulations and delivery systems show promise for blood substitute development.